ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ACCUPRIL
CHF and arrhythmias
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ACCUPRIL Rx

Generic Name and Formulations:
Quinapril (as HCl) 5mg+, 10mg, 20mg, 40mg; tabs; +scored.

Company:
Pfizer Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Indications for ACCUPRIL:

Heart failure inadequately controlled by diuretics and/or digitalis.

Adult Dose for ACCUPRIL:

Initially 5mg twice daily, if needed increase weekly to 20–40mg daily in 2 equally divided doses. In CHF with hyponatremia or renal impairment: initially 2.5–5mg once daily based on CrCl (see literature), if needed titrate dose under supervision.

Children's Dose for ACCUPRIL:

Not established.

Pharmacological Class:

ACE inhibitor.

Contraindications:

History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion. Renal or hepatic impairment. CHF. Dialysis (esp. high-flux membrane). Monitor renal function in severe CHF, hypertension, or renal artery stenosis. Monitor WBCs in renal or collagen vascular disease. Monitor for hyperkalemia in diabetics. Surgery. Discontinue if angioedema, laryngeal edema, jaundice or marked elevation in liver enzymes occurs. Black patients: increased risk of angioedema, possibly less effective. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers.

Interactions:

See Contraindications. K+ supplements, K+ sparing diuretics, K+ containing salt substitutes may cause hyperkalemia. May increase lithium levels; monitor frequently. Antagonizes tetracycline. Potentiated by diuretics. May be antagonized by NSAIDs including COX-2 inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Adverse Reactions:

Headache, dizziness, fatigue, cough, GI upset, hypotension, hyperkalemia, back pain, tachycardia, dry mouth, somnolence, sweating; rare: angioedema, anaphylactoid reactions, excessive hypotension, hepatic failure, neutropenia, agranulocytosis.

Metabolism:

Hepatic. 97% protein bound.

Elimination:

Renal.

Generic Availability:

YES

How Supplied:

Tabs—90

Indications for ACCUPRIL:

Hypertension.

Adult Dose for ACCUPRIL:

Monotherapy: initially 10–20mg once daily. Usual maintenance: 20–80mg daily in 1–2 divided doses. Elderly: initially 10mg once daily. Patients on diuretic: suspend diuretic for 2–3 days before starting; resume diuretic if BP not controlled by quinapril alone. If diuretic cannot be discontinued, or if creatinine clearance (CrCl) 30–60mL/min: initially 5mg daily. CrCl 10–30mL/min: initially 2.5mg daily.

Children's Dose for ACCUPRIL:

Not established.

Pharmacological Class:

ACE inhibitor.

Contraindications:

History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion. Renal or hepatic impairment. CHF. Dialysis (esp. high-flux membrane). Monitor renal function in severe CHF, hypertension, or renal artery stenosis. Monitor WBCs in renal or collagen vascular disease. Monitor for hyperkalemia in diabetics. Surgery. Discontinue if angioedema, laryngeal edema, jaundice or marked elevation in liver enzymes occurs. Black patients: increased risk of angioedema, possibly less effective. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers.

Interactions:

See Contraindications. K+ supplements, K+ sparing diuretics, K+ containing salt substitutes may cause hyperkalemia. May increase lithium levels; monitor frequently. Antagonizes tetracycline. Potentiated by diuretics. May be antagonized by NSAIDs including COX-2 inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.

Adverse Reactions:

Headache, dizziness, fatigue, cough, GI upset, hypotension, hyperkalemia, back pain, tachycardia, dry mouth, somnolence, sweating; rare: angioedema, anaphylactoid reactions, excessive hypotension, hepatic failure, neutropenia, agranulocytosis.

Metabolism:

Hepatic. 97% protein bound.

Elimination:

Renal.

Generic Availability:

YES

How Supplied:

Tabs—90

Sign Up for Free e-newsletters